PMID- 25963073
OWN - NLM
STAT- MEDLINE
DCOM- 20151112
LR  - 20220408
IS  - 1531-4995 (Electronic)
IS  - 0023-852X (Print)
IS  - 0023-852X (Linking)
VI  - 125
IP  - 9
DP  - 2015 Sep
TI  - MYB rearrangement and clinicopathologic characteristics in head and neck adenoid 
      cystic carcinoma.
PG  - E292-9
LID - 10.1002/lary.25356 [doi]
AB  - OBJECTIVES: Salivary gland adenoid cystic carcinoma (ACC) is rare, aggressive, 
      and challenging to treat. Many ACCs have a t(6;9) chromosomal translocation 
      resulting in a MYB-NFIB fusion gene, but the clinical significance is unclear. 
      The purposes of this study were to describe the clinicopathologic factors 
      impacting survival and to determine the prevalence and clinical significance of 
      MYB-NFIB fusion. STUDY DESIGN: Case series. METHODS: Medical records of patients 
      treated for ACC of the head and neck from 1974 to 2011 were reviewed and 
      clinicopathologic data recorded. Fluorescence in situ hybridization (FISH) was 
      used to detect MYB rearrangement in archival tumor tissue as a marker of MYB-NFIB 
      fusion. RESULTS: One hundred fifty-eight patients were included, with median 
      follow-up 75.1 months. Median overall survival was 171.5 months (95% confidence 
      interval [CI] = 131.9-191.6), and median disease-free survival was 112.0 months 
      (95% CI = 88.7-180.4). Advanced stage was associated with decreased overall 
      survival (adjusted ptrend  < 0.001), and positive margins were associated with 
      decreased disease-free survival (adjusted hazard ratio [aHR] = 8.80, 95% 
      CI = 1.25-62.12, P = 0.029). Ninety-one tumors were evaluable using FISH, and 59 
      (65%) had evidence of a MYB-NFIB fusion. MYB-NFIB positive tumors were more 
      likely than MYB-NFIB negative tumors to originate in minor salivary glands 
      (adjusted prevalence ratios = 1.51, 95% CI = 1.07-2.12, P = 0.019). MYB-NFIB 
      tumor status was not significantly associated with disease-free or overall 
      survival (hazard ratio [HR] = 1.53, 95% CI = 0.77-3.02, P = 0.22 and HR = 0.91, 
      95% CI = 0.46-1.83, P = 0.80, respectively, for MYB-NFIB positive compared with 
      MYB-NFIB negative tumors). CONCLUSION: Stage and margin status were important 
      prognostic factors for ACC. Tumors with evidence of MYB-NFIB fusion were more 
      likely to originate in minor salivary glands, but MYB-NFIB tumor status was not 
      significantly associated with prognosis. LEVEL OF EVIDENCE: 4.
CI  - (c) 2015 The American Laryngological, Rhinological and Otological Society, Inc.
FAU - Rettig, Eleni M
AU  - Rettig EM
AD  - Department of Otolaryngology-Head and Neck Surgery.
FAU - Tan, Marietta
AU  - Tan M
AD  - Department of Otolaryngology-Head and Neck Surgery.
FAU - Ling, Shizhang
AU  - Ling S
AD  - Department of Otolaryngology-Head and Neck Surgery.
FAU - Yonescu, Raluca
AU  - Yonescu R
AD  - Department of Pathology, Johns Hopkins University School of Medicine.
FAU - Bishop, Justin A
AU  - Bishop JA
AD  - Department of Pathology, Johns Hopkins University School of Medicine.
FAU - Fakhry, Carole
AU  - Fakhry C
AD  - Department of Otolaryngology-Head and Neck Surgery.
AD  - Milton J. Dance Jr. Head and Neck Center, Greater Baltimore Medical Center.
AD  - Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 
      Baltimore, Maryland, U.S.A.
FAU - Ha, Patrick K
AU  - Ha PK
AD  - Department of Otolaryngology-Head and Neck Surgery.
AD  - Milton J. Dance Jr. Head and Neck Center, Greater Baltimore Medical Center.
LA  - eng
GR  - R01 DE023227/DE/NIDCR NIH HHS/United States
GR  - T32 DC000027/DC/NIDCD NIH HHS/United States
GR  - 2T32DC000027-26/DC/NIDCD NIH HHS/United States
GR  - R01-DE023227/DE/NIDCR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20150511
PL  - United States
TA  - Laryngoscope
JT  - The Laryngoscope
JID - 8607378
RN  - 0 (DNA, Neoplasm)
RN  - 0 (MYB-NFIB fusion protein, human)
RN  - 0 (Oncogene Proteins, Fusion)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Adenoid Cystic/*genetics/mortality/pathology
MH  - DNA, Neoplasm/*genetics
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - Gene Rearrangement/*genetics
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - *Neoplasm Staging
MH  - Oncogene Proteins, Fusion/*genetics
MH  - Retrospective Studies
MH  - Salivary Gland Neoplasms/*genetics/mortality/pathology
MH  - Survival Rate/trends
MH  - Young Adult
PMC - PMC4546892
MID - NIHMS681580
OTO - NOTNLM
OT  - Adenoid cystic carcinoma
OT  - MYB
OT  - MYB-NFIB fusion gene
OT  - disease-free survival
OT  - minor salivary glands
OT  - salivary gland neoplasms
OT  - survival
COIS- Conflict of interest: The authors report no conflict of interest.
EDAT- 2015/05/13 06:00
MHDA- 2015/11/13 06:00
PMCR- 2016/09/01
CRDT- 2015/05/13 06:00
PHST- 2015/01/13 00:00 [received]
PHST- 2015/03/31 00:00 [revised]
PHST- 2015/04/03 00:00 [accepted]
PHST- 2015/05/13 06:00 [entrez]
PHST- 2015/05/13 06:00 [pubmed]
PHST- 2015/11/13 06:00 [medline]
PHST- 2016/09/01 00:00 [pmc-release]
AID - 10.1002/lary.25356 [doi]
PST - ppublish
SO  - Laryngoscope. 2015 Sep;125(9):E292-9. doi: 10.1002/lary.25356. Epub 2015 May 11.